Test drug OSE-279 for advanced lung cancer that has no key mutations
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to sign informed consent before any study steps
- Have good overall physical function (ECOG 0–1, meaning fully active or limited but ambulatory)
- Have an HLA-A2 blood test result (HLA-A2 positive is required for Parts B/C; some HLA-A2–negative may be allowed in a later part)
- Have advanced stage IV NSCLC that cannot be treated with sure surgery or radiation, and your tumor must not have certain targeted-therapy mutations (EGFR/ALK/ROS1) or you must not qualify for first-line targeted therapy
- Have measurable tumors on scans (at least one measurable lesion) and have enough blood counts, kidney, and liver function for treatment
- You must not have had prior systemic (whole-body) cancer treatment for metastatic disease in the first-line setting, including immunotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
This trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with lung cancer that has spread to a few spots. It aims to see if this combination improves control of the disease.
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.